3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
2
NIH
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
268
Lymphoid
30
Thoracic
22
Other solid neoplasm
20
Gynecologic
13
Tumor-Agnostic
11
Head & Neck
10
Genitourinary
7
Breast
7
Sarcoma
4
Dermatologic
4
Other hematologic neoplasm
3
CNS
3
Plasma cell
1
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
Everolimus
23
pasireotide
14
lutetium Lu 177 dotatate
10
Octreotide
10
lanreotide
9
surufatinib
8
Carboplatin
8
Paclitaxel
7
pembrolizumab
5
amino-acid, glucose, and electrolyte solution
5
Thyrotropin Alfa
5
Sunitinib
5
Nivolumab
5
Injections
5
3-Iodobenzylguanidine
5
relacorilant
4
fosbretabulin
4
Temozolomide
4
Fulvestrant
4
Etoposide
4
Data Collection
4
Cisplatin
4
vandetanib
3
selpercatinib
3
dabrafenib
3
anlotinib
3
Mifepristone
3
Lutetium-177
3
Lutetium
3
Irinotecan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Oxaliplatin
×
Endocrine
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled